NCT05469347 (PALMS) is a Phase 1 clinical trial of Alirocumab in Sepsis, sponsored by Jonathan Sevransky.

Who is sponsoring NCT05469347?

NCT05469347 is sponsored by Jonathan Sevransky.

What drugs are being tested in NCT05469347?

Interventions in NCT05469347: Alirocumab, Placebo.

Is NCT05469347 still recruiting?

NCT05469347 is currently completed. Last updated 24 March 2025.

Last reviewed 2025-03-24 · How we verify

NCT05469347: PALMS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alirocumab in Patients with Sepsis

Completed Phase 1 Last updated 24 March 2025

What this trial tests

Phase 1 trial testing Alirocumab in Sepsis in 50 participants. Completed in 23 February 2025.

Timeline

4 January 2023

Primary endpoint
18 February 2025

23 February 2025

Quick facts

Lead sponsor	Jonathan Sevransky
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	4 January 2023
Primary completion	18 February 2025
Estimated completion	23 February 2025
Sites	2 locations across United States

Drugs / interventions tested

Alirocumab (ALIROCUMAB) — full drug profile →
Placebo

Conditions studied

Sepsis — all drugs for Sepsis →

Sponsor

Jonathan Sevransky

Who can join

Adults 18 to 90, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether the drug alirocumab, which may lower cholesterol, can reduce the amount of inflammation caused by an infection that has caused either low blood pressure or difficulty breathing. Participants will be randomized to receive a single IV infusion of alirocumab or a placebo.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

From geroscience to precision geromedicine: Understanding and managing aging.
Kroemer G, Maier AB, Cuervo AM, Gladyshev VN, et al · · 2025 · cited 139× · PMID 40250404 · DOI 10.1016/j.cell.2025.03.011
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.
Bao X, Liang Y, Chang H, Cai T, et al · · 2024 · cited 101× · PMID 38185721 · DOI 10.1038/s41392-023-01690-3
The evolving landscape of PCSK9 inhibition in cancer.
Oza PP, Kashfi K. · · 2023 · cited 32× · PMID 37059376 · DOI 10.1016/j.ejphar.2023.175721
Dysregulation of Neutrophil-Endothelial Communication in Sepsis: Mechanisms and Therapeutic Perspectives.
Esmalian Afyouni N, Kiani MF, Kilpatrick LE. · · 2026 · PMID 41972674 · DOI 10.3390/cells15070581

Verify or expand the search:

Other trials of Alirocumab

Trials testing the same drug.

NCT07477704 — A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemi · Phase 2 · not yet recruiting
NCT06858332 — Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia · recruiting
NCT06385262 — TOP 2301: Neoadjuvant Chemo for NSCLC · Phase 2 · suspended
NCT06080256 — Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS) · Phase 3 · unknown
NCT06083961 — The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis · Phase 4 · not yet recruiting

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05469347 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonathan Sevransky
Last refreshed: 24 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05469347.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing